Predictors of hepatitis B virus genotype and viraemia in HIV-infected patients with chronic hepatitis B in Europe

Vincent Soriano1*, Amanda Mocroft2, Lars Peters3, Juergen Rockstroh4, Francisco Antunes5, Nikolai Kirkby6, Stephane de Wit7, Antonella d’Arminio Monforte8, Robert Flisiak9 and Jens Lundgren3,6 on behalf of EuroSIDA†

1Department of Infectious Diseases, Hospital Carlos III, Madrid, Spain; 2University College Medical School, Royal Free Campus, London, UK; 3Copenhagen HIV Programme, University of Copenhagen, Copenhagen, Denmark; 4University of Bonn, Bonn, Germany; 5Hospital Santa Maria, Lisbon, Portugal; 6Centre for Viral Disease/KMA, Rigshospitalet, Copenhagen, Denmark; 7Centre Hospitalier Universitaire Saint-Pierre, Brussels, Belgium; 8Ospedale San Paolo, Milan, Italy; 9Medical University, Białystok, Poland

*Corresponding author. Department of Infectious Diseases, Hospital Carlos III, Calle Sinesio Delgado 10, 28029 Madrid, Spain. Tel: +34-91-4532500; Fax: +34-91-7336614; E-mail: vsoriano@dragonet.es
†Members of the study group are listed in the Acknowledgements.

Background: Both natural history and treatment outcome of hepatitis B virus (HBV) infection are influenced by genotypes and viral load. Information about factors determining HBV genotype distribution and viraemia in HIV/HBV-co-infected patients is scarce.

Methods: All HIV-positive patients living in Europe and Argentina recruited in EuroSIDA (1994–2006) were tested for serum HBV surface antigen (HBsAg). Chronic carriers were further characterized virologically at one central laboratory. Variables influencing HBV genotype distribution and viraemia were assessed using logistic regression.

Results: From 16505 HIV patients enrolled in EuroSIDA, 1179 (7.1%) were HBsAg positive, of whom 474 had specimens that allowed inclusion in the virological substudy. Overall 293 (62%) were treated with anti-HBV active antiretroviral drugs at the time of testing. Hepatitis delta virus superinfection was recognized in 14% and hepatitis C virus (HCV) antibodies in 27%. Serum HBV DNA was detectable in 315 (66.5%) and HBV genotyping gave results in 170 (35.9%) patients. HBV genotype distribution was as follows: A (72.9%), D (17.1%), G (1.8%), E (1.2%), F (1.2%) and C (0.6%); another 5.9% were co-infected with multiple HBV genotypes. In the multivariate analysis, the best predictor of HBV genotype A infection was risk exposure other than intravenous drug use, whereas predictors for detectable HBV viraemia were lower CD4 counts and lack of HCV antibodies.

Conclusion: A substantial proportion of HIV-positive patients with chronic hepatitis B show detectable HBV viraemia despite being treated with anti-HBV active antiretroviral drugs (mainly lamivudine). Low CD4 counts were associated with an independent higher risk of detectable HBV viraemia, which supports an earlier introduction of antiretroviral therapy, including anti-HBV drug(s) more potent than lamivudine.

Keywords: epidemiology, HBV genotypes, HBV viraemia

Introduction

Chronic hepatitis B virus (HBV) infection currently affects 5%–10% of individuals with HIV infection in developed countries, despite HBV vaccination being widely available and successful for preventing HBV infection. Co-infection with HIV alters the natural history of chronic hepatitis B, with higher serum HBV DNA concentrations, lower liver enzyme values and faster progression to liver cirrhosis, particularly in those with low CD4 counts. Liver-related mortality has now become one of the leading causes of non-AIDS deaths among HIV-positive persons in developed regions, where antiretroviral therapy is widely used, and chronic hepatitis B and/or C are the major contributors.

Only recently it has become apparent that serum HBV DNA level is one, if not the major, determinant of the speed of liver disease progression in patients with chronic hepatitis B. On the basis of this observation, most current guidelines recommend considering HBV therapy in patients with serum HBV DNA > 2000 IU/mL. Moreover, different HBV genotypes may...
show distinct behaviour in terms of natural history\textsuperscript{12,13} and response to therapy.\textsuperscript{14,15} Information about HBV genotype distribution and viraemia in HIV/HBV-co-infected patients is scarce.\textsuperscript{15} This knowledge is important since several new antiviral agents active against HBV have recently been approved, some of which are dually active against HBV and HIV.\textsuperscript{2,15} The aim of this study was to describe the virological characteristics of HIV-infected patients with chronic hepatitis B in the EuroSIDA cohort.

**Patients and methods**

**Study population**

EuroSIDA is a prospective study of 16505 HIV-1-infected patients at 93 centres across Europe, Israel and Argentina; further details have been reported elsewhere.\textsuperscript{16} Briefly, for each cohort the centres provide data on consecutive patients seen at the outpatient clinics beginning in May 1994 until a pre-defined number of patients enrol from each site. To date, eight cohorts of patients have been recruited. Data are collected prospectively at clinical sites and are extracted and sent to the coordinating centre at 6 monthly intervals. For cohorts I–III, eligible patients were those who had had a CD4 count <500 cells/mm\textsuperscript{3} during the previous 4 months. The CD4 count restriction was removed for cohorts IV–VII. At recruitment, in addition to demographic and clinical information, a complete antiretroviral treatment history is obtained, together with the most recent CD4 count and plasma HIV RNA measurements. At each follow-up visit, details on all CD4 counts and plasma HIV RNA values measured since the last follow-up visit are extracted, as are the dates of starting and stopping each antiretroviral drug received and the use of drugs for prophylaxis against opportunistic infections. The dates of diagnosis of all AIDS-defining illnesses, non-AIDS-defining malignancies and other serious infections are also recorded. The present analysis includes follow-up to a median date of January 2008.

Information on serum HBV surface antigen (HBsAg) status in EuroSIDA has been collected since 1997; patients who died or were lost to follow-up before this date did not routinely have information on HBsAg collected. Centres which have determined HBsAg genotype or measured HBV DNA after 1997 report test results to the coordinating centre via the data collection form details at www.cphiv.dk. The EuroSIDA plasma repository was set up in 1997 and collects plasma samples from all HIV patients at 6 monthly intervals. Patients with unknown HBsAg status and with a stored plasma sample were identified in 2006 and HBsAg status determined. Patients who tested HBsAg positive were then tested for serum HBV DNA and genotyped in a central laboratory. In addition, patients with unknown HBV genotype, but reported to be HBsAg positive by the centres who had stored samples, were identified in 2006 and HBsAg-positive patients excluded from this analysis were less likely to have been infected via homosexual exposure ($P=0.0038$), were less likely to be from Central or Northern Europe ($P<0.001$), were slightly younger ($P=0.012$) and were recruited into EuroSIDA more recently ($P<0.0001$).

The main characteristics of the 474 HIV/HBV study population are depicted in Table 1. Most individuals were male (84%), Caucasian (85%), and men who have sex with men (MSM) (51%). Median age was 38 years. Median CD4 count was 295 cells/mm\textsuperscript{3}. Overall, 91% were or had been exposed previously to antiretroviral therapy, of whom 293 (62%) included at least one anti-HBV active agent at the time of testing. Hepatitis delta virus (HDV) superinfection was recognized in 14% and hepatitis C virus (HCV) antibodies in 27% of patients.

Serum HBV DNA was detectable in 315 (66.5%) out of 474 HBsAg-positive patients. HBV genotype could be obtained for 170 (54.0%) HBV viraemic patients. Lack of HBV genotype results in the remaining HBsAg-positive specimens was mainly due to too low serum HBV DNA concentrations. HBV genotype distribution was as follows: A (124, 72.9%), D (29, 17.1%), G (3, 1.8%), E (2, 1.2%), F (2, 1.2%) and C (1; 0.6%); another 5.9% were co-infected with multiple HBV genotypes (5 A/D, 3 A/G, 1 A/D/G).

There were significant differences in the regional distribution of HBV genotypes ($P=0.0031$). As shown in Figure 1, HBV genotype A was the predominant variant in all regions except South Europe/Argentina, where non-A genotypes (mainly genotype D) were similarly prevalent. In Northern Europe, HBV genotype A was by far the most frequent HBV variant.

Of 124 patients infected with HBV genotype A, only 3 (2.4%) were female, compared with ~20% of those with non-A genotypes or unknown genotypes ($P<0.0001$). Similarly, only 12% of patients with HBV genotype A were infected through intravenous drug use compared with 54% of those with non-A genotypes and 26% of those with unknown HBV genotypes ($P<0.0001$). Patients with non-A genotypes were more likely to be co-infected with HCV (50%), compared with patients with unknown HBV genotypes (31%) or genotype A (10.5%) ($P<0.0001$). In addition, patients with unknown HBV genotypes had significantly higher CD4 counts at baseline (326 cells/mm\textsuperscript{3})

**Statistical analysis**

Characteristics of patients were compared using $\chi^2$ tests for categorical variables and non-parametric Wilcoxon or Kruskal–Wallis tests for continuous variables. Patients were categorized into three groups: HBV genotype A, non-A genotypes and patients without a recorded genotype. Logistic regression, using forward selection with entry criteria of $P<0.01$, was used to identify which factors were associated with genotype A versus non-genotype A (excluding patients for whom a genotype could not be determined), and for comparisons between subjects with undetectable serum HBV DNA and viraemic patients. Baseline was defined as the date of the serum sample. All data were analysed using SAS version 9.1 (Statistical Analysis Software, Cary, NC, USA).

**Quantification of HBV viraemia and genotyping**

Serum HBV DNA was measured in all HBsAg-positive samples using a bDNA assay (Versant HBV v3.0, Siemens, Berkeley, CA, USA), which is a signal amplification procedure with a linear dynamic range from 357 to 18x$10^5$ IU/ml.\textsuperscript{17} HBV genotyping was performed using the LiPA HBV genotype v2.0 assay (Innogenetics, Ghent, Belgium), a commercial hybridization line probe assay that detects specific sequences in the S region of the HBV genome.\textsuperscript{18}
compared with patients with genotype A (237 cells/mm$^3$) or non-A genotypes (244 cells/mm$^3$) ($P=0.0004$). Interestingly, those with non-A genotypes had the highest CD4 nadir prior to baseline ($P=0.0006$). Patients with HBV genotype A had significantly higher median serum HBV DNA levels (178,571,000 IU/mL) compared with non-A genotypes (25,121,300 IU/mL) or unknown genotypes (357 IU/mL) ($P<0.0001$).

In the multivariate analysis, the only factors associated with being infected with HBV genotype A versus all other genotypes (patients with unknown genotypes were excluded from the analysis) were HIV exposure category and region of Europe. Compared with intravenous drug users (IDUs), MSM had a 10-fold increased risk of infection with HBV genotype A (Figure 2). After adjustment, compared with patients from Southern Europe/Argentina, HIV/HBsAg-positive patients from northern Europe tended to be more frequently infected with HBV genotype A ($P=0.054$), but most probably this was a surrogate of more common homosexual behaviour there.

Table 1. Main baseline characteristics of the HIV/HBV-co-infected study population

<table>
<thead>
<tr>
<th></th>
<th>All patients</th>
<th>Genotype A</th>
<th>Genotype non-A</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>n=474 (100%)</td>
<td>n=124 (23.4%)</td>
<td>n=46 (8.7%)</td>
<td></td>
</tr>
<tr>
<td>Gender</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>male</td>
<td>400 (84.4)</td>
<td>121 (97.6)</td>
<td>37 (80.4)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>female</td>
<td>74 (15.6)</td>
<td>3 (2.4)</td>
<td>9 (19.6)</td>
<td></td>
</tr>
<tr>
<td>HIV risk category</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MSM</td>
<td>243 (51.3)</td>
<td>95 (76.6)</td>
<td>15 (32.6)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>IDU</td>
<td>116 (24.5)</td>
<td>12 (9.7)</td>
<td>25 (54.3)</td>
<td></td>
</tr>
<tr>
<td>heterosexual</td>
<td>71 (15.0)</td>
<td>7 (5.6)</td>
<td>4 (8.7)</td>
<td></td>
</tr>
<tr>
<td>other</td>
<td>44 (9.3)</td>
<td>10 (8.1)</td>
<td>2 (4.4)</td>
<td></td>
</tr>
<tr>
<td>Ethnic origin</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>white</td>
<td>403 (85.0)</td>
<td>110 (88.7)</td>
<td>39 (84.8)</td>
<td>0.40</td>
</tr>
<tr>
<td>other</td>
<td>41 (15.0)</td>
<td>14 (11.3)</td>
<td>7 (15.2)</td>
<td></td>
</tr>
<tr>
<td>HCV antibody</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>negative</td>
<td>284 (59.9)</td>
<td>91 (73.4)</td>
<td>20 (43.5)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>positive</td>
<td>127 (26.8)</td>
<td>11 (8.9)</td>
<td>22 (47.8)</td>
<td></td>
</tr>
<tr>
<td>unknown</td>
<td>63 (13.3)</td>
<td>22 (17.7)</td>
<td>4 (8.7)</td>
<td></td>
</tr>
<tr>
<td>HDV antibodies</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>negative</td>
<td>386 (81.4)</td>
<td>103 (83.1)</td>
<td>27 (58.7)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>positive</td>
<td>63 (13.3)</td>
<td>6 (4.8)</td>
<td>16 (34.8)</td>
<td></td>
</tr>
<tr>
<td>unknown</td>
<td>25 (5.3)</td>
<td>15 (12.1)</td>
<td>3 (6.5)</td>
<td></td>
</tr>
<tr>
<td>Prior AIDS</td>
<td>144 (30.4)</td>
<td>44 (35.5)</td>
<td>14 (20.4)</td>
<td>0.34</td>
</tr>
<tr>
<td>ARVs at/before baseline</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>naive</td>
<td>44 (9.3)</td>
<td>11 (8.9)</td>
<td>4 (8.7)</td>
<td>0.81</td>
</tr>
<tr>
<td>ART</td>
<td>81 (17.1)</td>
<td>25 (20.2)</td>
<td>9 (19.6)</td>
<td></td>
</tr>
<tr>
<td>cART</td>
<td>349 (73.6)</td>
<td>88 (71.0)</td>
<td>33 (71.7)</td>
<td></td>
</tr>
<tr>
<td>Baseline date (month/year)</td>
<td>12/98 (5/97–1/02)</td>
<td>11/98 (3/97–7/00)</td>
<td>2/98 (5/97–1/02)</td>
<td>0.015</td>
</tr>
<tr>
<td>CD4 count (cells/mm$^3$)</td>
<td>295 (165–450)</td>
<td>237 (115–386)</td>
<td>244 (108–431)</td>
<td>0.0004</td>
</tr>
<tr>
<td>CD4 nadir (cells/mm$^3$)</td>
<td>140 (57–238)</td>
<td>101 (31–189)</td>
<td>173 (52–244)</td>
<td>0.0006</td>
</tr>
<tr>
<td>Plasma HIV RNA (log$_{10}$ copies/mL)</td>
<td>2.70 (1.81–4.00)</td>
<td>3.00 (1.93–4.34)</td>
<td>2.70 (1.90–4.09)</td>
<td>0.15</td>
</tr>
<tr>
<td>Age (years)</td>
<td>37.8 (33.1–45.3)</td>
<td>38.2 (33.4–45.5)</td>
<td>35.3 (30.7–41.5)</td>
<td>0.10</td>
</tr>
<tr>
<td>Time since first HBsAg+ test (years)</td>
<td>1.0 (0.2–3.0)</td>
<td>1.3 (0.3–2.7)</td>
<td>1.8 (0.4–3.3)</td>
<td>0.18</td>
</tr>
<tr>
<td>Serum HBV DNA (log$_{10}$ IU/mL)</td>
<td>2.8 (2.6–5.7)</td>
<td>7.3 (5.5–7.3)</td>
<td>6.4 (4.4–7.3)</td>
<td>&lt;0.0001</td>
</tr>
</tbody>
</table>

MSM, men who have sex with men; IDU, intravenous drug user; ARVs, antiretrovirals; ART, antiretroviral therapy; cART, combination antiretroviral therapy.
Overall, 159 HBsAg-positive patients [33.5%, 95% confidence interval (CI) 29.3%–37.7%] had serum HBV DNA, 357 IU/mL. Conversely, 96 patients (20.3%) had serum HBV DNA, 107 IU/mL. It should be highlighted that HBV genotype distribution tended to differ comparing distinct HBV viral load strata; up to 75/124 (60.5%) of HBV genotype A showed serum HBV DNA >10^7 IU/mL compared with 21/46 (45.7%) of non-A genotypes (P=0.083).

Table 2 splits up the study population into different strata of HBV viral load taking into account exposure to distinct anti-HBV agents. Overall, serum HBV DNA levels >2000 IU/mL, which

---

**Figure 1.** Regional distribution of hepatitis B virus genotypes. This figure appears in colour in the online version of *JAC* and in black and white in the print version of *JAC.*

**Figure 2.** HBV genotype distribution (A versus non-A) according to risk group and region (adjusted odds).
have been associated with an increased risk of liver-related complications\(^7\)–\(^9\) and with indication for HBV therapy,\(^10,11\) were recognized in 76 out of 181 patients (42%) not receiving anti-HBV drugs. In the extreme, serum HBV DNA levels \(10^7\) IU/mL, which are associated with low response to either interferon or oral nucleoside analogues, were recognized in 53 (69.7%) patients.

Of 293 patients who included anti-HBV agents as part of the antiretroviral regimen, only 105 (35.8%) had undetectable HBV viremia, which was slightly higher in patients receiving tenofovir than lamivudine as the only anti-HBV agent (45.4% versus 35.2%; \(P=0.3\)).

Overall, 293 (61.8%) out of 474 HIV/HBV-co-infected patients were taking anti-HBV antiretroviral agents at the time of testing. They were receiving lamivudine (\(n=281;\) 59.3%), tenofovir (\(n=22;\) 4.6%) and/or emtricitabine (\(n=4;\) 0.8%). There were no statistically significant differences when comparing HBV genotype groups in the proportion of patients receiving any anti-HBV agent (data not shown). In addition, there were no differences in the proportion of patients who had ever started anti-HBV treatment when comparing those who were currently aviraemic (105/159; 66%) versus those who were viraemic (188/315; 59.7%) (\(P=0.18\)). In contrast, in the group of patients who had started anti-HBV therapy there was a higher proportion with serum HBV DNA \(<10^7\) IU/mL (250/378; 66.1%) than with HBV DNA \(>10^7\) IU/mL (43/96; 44.8%) (\(P=0.0001\)).

Table 3 records the results of the univariate and multivariate analysis of factors associated with being HBV aviraemic. After adjustment, patients with a higher CD4 count at baseline were more frequently aviraemic \(\text{OR} 1.24\) per each 2-fold increase of CD4 values, as well as more frequently HCV antibody positive \(\text{OR} 1.73\).

Of 449 HIV/HBsAg-positive patients tested for anti-HDV antibodies, 63 were positive (14.0%; 95% CI 10.9%–17.1%). Among 109 patients with HBV genotype A, 6 (5.5%) were anti-HDV antibody positive, compared with 16/43 (37.2%) with non-A genotypes and 41/297 (13.8%) with unknown genotypes \((P<0.0001)\). There were no significant differences in the proportions of patients who were anti-HDV antibody positive comparing those who were HBV DNA viraemic (36/291; 12.4%) and aviraemic (27/158; 17.1%) \((P=0.17)\), or comparing patients with serum HBV DNA \(<10^7\) IU/mL (57/368; 15.5%) or \(>10^7\) IU/mL (6/81; 7.4%) \((P=0.058)\). Finally, the median serum HBV DNA level was slightly lower in those who were anti-HDV antibody positive \(2.6 \log_{10} \text{IU/mL},\) interquartile range (IQR)
2.6–3.0 log_{10} IU/mL] compared with those who were anti-HDV antibody negative [2.8 log_{10} IU/mL, IQR 2.6–5.7 log_{10} IU/mL] (P=0.012).

Discussion

Co-infection with HBV complicates the management of HIV-infected individuals. On the one hand, liver-related events, including decompensated cirrhosis and hepatocellular carcinoma, appear more frequently in co-infected patients than in HBV-monoinfected individuals. Suppression of HBV replication by treatment with anti-HBV agents represents the best way to prevent progression of liver disease in these patients. On the other hand, the use of antiretroviral agents to treat HIV-associated immunodeficiency is challenged by an increased risk of hepatotoxicity in subjects with underlying chronic hepatitis B. A further complication derives from the fact that some antiviral agents possess dual activity against both HIV and HBV, and therefore have to be doubly monitored, avoiding selection of drug resistance by either virus, as recently highlighted in HBV. and therefore have to be doubly monitored, avoiding selection of drug resistance by either virus, as recently highlighted in HBV.

In the EuroSIDA study, two-thirds of HIV-positive patients with chronic hepatitis B showed detectable HBV viraemia despite almost two-thirds of them being treated with antiretroviral therapy including active anti-HBV drugs. It should be noted, however, that the study was conducted retrospectively on specimens collected from 1996 until 2008, and lamivudine was by far the most frequently prescribed single anti-HBV agent as part of any antiretroviral regimen. It is well known that the risk of selection of lamivudine resistance in HBV is increased in HIV-co-infected individuals. More recently tenofovir and the combination of tenofovir plus emtricitabine (Truvada®) have replaced lamivudine as the preferred choice in HIV/HBV-co-infected patients. Tenofovir either alone or in combination ensures a more durable suppression of HBV replication, and preliminary evidence suggests that this effect may be associated with a halt and regression of HBV-related liver fibrosis in HIV/HBV-co-infected patients. Although we could not record liver fibrosis staging in the EuroSIDA population, the recognition of detectable HBV viraemia in 66% of the co-infected population should reinforce the need to monitor and treat appropriately chronic hepatitis B in HIV-positive patients. It is worrisome that nearly one-third of the 91% of HIV/HBV-co-infected patients who received antiretroviral therapy in our study did not receive any anti-HBV agent. As pointed out by others, chronic hepatitis B has unfortunately been neglected in the HIV-co-infected individuals. A second limitation of our study was by far the most prevalently infected genotype A (73%) which was in contrast, non-A genotypes were more often found in IDUs, and not surprisingly up to 50% of them were also HCV antibody positive. It is noteworthy that HBV genotype A patients tended to show significantly higher serum HBV DNA levels, regardless of anti-HBV drug exposure. This is important since HBV viraemia is associated with the risk of liver-related complications and selection of HBV drug resistance.

In summary, a substantial proportion of HIV-positive patients with chronic hepatitis B in EuroSIDA showed detectable HBV viraemia until recently, despite many of them being treated with active anti-HBV antiretroviral drugs (mainly lamivudine). Low
CD4 counts are associated with an independent higher risk of detectable HBV viremia, which further supports recent recommendations in favour of an earlier introduction of antiretroviral therapy, including anti-HBV drug(s) more potent than lamivudine alone, in HIV/HBV co-infected patients.

Acknowledgements

Members of the EuroSIDA Study Group are listed below (National coordinators are shown in parentheses).

Argentina: (M Lozano), C Elias, Hospital JM Ramos Mejia, Buenos Aires.
Bulgaria: K Kostov, Infectious Diseases Hospital, Sofia; M Vesselinov, Infectious Diseases Hospital, Plovdiv.
Croatia: K Kostov, Infectious Diseases Hospital, Zagreb; J Grgur, General Hospital, Osijek.
Czech Republic: (L Macholík) H Rozsypal, Faculty Hospital Bulovka, Prague; D Sedlacek, Charles University Hospital, Pizen.
Denmark: (J Nielsen) G Republic: (L Machalá) H Rozsypal, Faculty Hospital Bulovka, Prague; D Sedlacek, Charles University Hospital, Pizen.
England: (M Valerio) G E Swingler, St. George's Hospital, London; S Metcalfe, Imperial College School of Medicine at St. Mary's, London.
Finland: (M Ristola), Helsinki University Central Hospital, Helsinki.
France: (C Katlama) Hoˆpital de la Pitie ´-Salpe´tie`re, Paris; J-P Kohtla-Jarvene, Helsinki University Central Hospital, Helsinki.
Germany: (J Gatell), Roche, Berlin.; F Dabis, D Neau, Unite ´ INSERM, Bordeaux.
Ireland: (F Mulcahy) St. James's Hospital, Dublin.
Italy: (A Chiesi) Istituto Superiore di Sanita’, Rome; R Esposito, I Muzo, C Mussini, Universita di Modena, Modena; C Arici, Ospedale Riuniti, Bergamo; R Pristera, Ospedale Generale Regionale, Montesarchio, M Gargiulo, Presidio Ospedaliero AD Cotugno, Monaldi Ospedale Riuniti, Bergamo; R Pristera, Ospedale Generale Regionale, Montesarchio, M Gargiulo, Presidio Ospedaliero AD Cotugno, Monaldi.
Luxembourg. The Netherlands: (P Reiss) Academisch Medisch Centrum, Amsterdam.
Netherlands: (P Reiss) Academisch Medisch Centrum, Amsterdam.
Norway: (J Bruun), A Mocroft, Royal Free and University College London Medical School, London (University College Campus); A Philips, MA Johnson, A Mocroft, Royal Free and University College Medical School, London (Royal Free Campus); M Murphy, Medical College of Saint Bartholomew's Hospital, London; J Weber, G Scullard, Imperial College School of Medicine at St. Mary's, London; M Fisher, Royal Sussex County Hospital, Brighton; C Leen, Western General Hospital, Edinburgh.
Poland: (B Knysz), J Jablonowska), E Malolepsza, K Wojcik, Wojewodzki Szpital Specjalistyczny, Lodz. Portugal: (F Antunes), E Valadas, Hospital Santa Maria, Lisbon; K Mansinho, Hospital de Egas Moniz, Lisbon; F Maltez, Hospital Curry Cabral, Lisbon. Romania: (D Duiculescu) Spitalul de Boli Infectioase si Tropicale; Dr. Victor Babes, Bucharest. Russia: (A Rakhmanova) Medical Academy Botkin Hospital, St. Petersburg, E Vinogradova, St. Petersburg AIDS Centre, St. Petersburg; S Buzunova, Novгород Centre for AIDS, Novgorod. Serbia: (J Jevtic) The Institute for Infectious and Tropical Diseases, Belgrade. Slovakia: (M Mokrás), D Staneková, Dérer Hospital, Bratislava. Slovenia: (J Tomažic) University Clinical Centre Ljubljana, Ljubljana. Spain: (J González-Lahoz), V Soriano, L Martin-Carbonero, P Labarga, Hospital Carlos III, Madrid; (S Moreno) Hospital Ramon y Cajal, Madrid; B Cloet, A Jou, R Paredes, Hospital Germans Trias i Pujol, Badalona; JM Gatell, JM Miró, Hospital Clinic i Provincial, Barcelona; P Domingo, M Gutierrez, G Mateo, MA Sambeat, Hospital Sant Pau, Barcelona. Sweden: (A Karlsson) Karolinska University Hospital, Stockholm; PO Persson, Karolinska University Hospital, Huddinge; L Flamholt, Malmo University Hospital, Malmo. Switzerland: (B Ledergerber), R Weber, University Hospital, Zurich; P Francioli, M Cavassini, Centre Hospitalier Universitaire Vaudois, Lausanne; B Hirschel, E Bossi, Hospital Cantonal Universitaire de Geneve, Geneve; H Furrer, Inselspital Bern, Bern; M Battegay, L Elzi, University Hospital Basel. Ukraine: (E Kravchenko), N Chentsova, Kiev Centre for AIDS, Kiev; (G Kutysyn) Luhansk AIDS Center, Luhansk; (S Servitskij) Odessa Region AIDS Center, Odessa; (S Antoniak) Kiev; (M Krasov) Kharkov State Medical University, Kharkov. UK: (S Barton) St. Stephen's Clinic, Chelsea and Westminster Hospital, London; AM Johnson, D Mercy, Royal Free and University College London Medical School, London (University College Campus); A Philips, MA Johnson, A Mocroft, Royal Free and University College Medical School, London (Royal Free Campus); M Murphy, Medical College of Saint Bartholomew's Hospital, London; J Weber, G Scullard, Imperial College School of Medicine at St. Mary's, London; M Fisher, Royal Sussex County Hospital, Brighton; C Leen, Western General Hospital, Edinburgh.

Virology group: B Cloet, R Paredes (Central Coordinators) plus ad hoc virologists from participating sites in the EuroSIDA Study.

Steering Committee: F Antunes, B Cloet, D Duiculescu, J Gatell, B Gazzard, A Horban, A Karlsson, C Katlama, B Ledergerber (Chair), A D'Arminio Monforte, Istituto Di Clinica Malattie Infettive, Rome; L Martin-Carbonero, P Labarga, Hospital Carlos III, Madrid; (S Moreno) Hospital Ramon y Cajal, Madrid; B Cloet, A Jou, R Paredes, Hospital Germans Trias i Pujol, Badalona; JM Gatell, JM Miró, Hospital Clinic i Provincial, Barcelona; P Domingo, M Gutierrez, G Mateo, MA Sambeat, Hospital Sant Pau, Barcelona. Sweden: (A Karlsson) Karolinska University Hospital, Stockholm; PO Persson, Karolinska University Hospital, Huddinge; L Flamholt, Malmo University Hospital, Malmo. Switzerland: (B Ledergerber), R Weber, University Hospital, Zurich; P Francioli, M Cavassini, Centre Hospitalier Universitaire Vaudois, Lausanne; B Hirschel, E Bossi, Hospital Cantonal Universitaire de Geneve, Geneve; H Furrer, Inselspital Bern, Bern; M Battegay, L Elzi, University Hospital Basel. Ukraine: (E Kravchenko), N Chentsova, Kiev Centre for AIDS, Kiev; (G Kutysyn) Luhansk AIDS Center, Luhansk; (S Servitskij) Odessa Region AIDS Center, Odessa; (S Antoniak) Kiev; (M Krasov) Kharkov State Medical University, Kharkov. UK: (S Barton) St. Stephen’s Clinic, Chelsea and Westminster Hospital, London; AM Johnson, D Mercy, Royal Free and University College London Medical School, London (University College Campus); A Philips, MA Johnson, A Mocroft, Royal Free and University College Medical School, London (Royal Free Campus); M Murphy, Medical College of Saint Bartholomew’s Hospital, London; J Weber, G Scullard, Imperial College School of Medicine at St. Mary’s, London; M Fisher, Royal Sussex County Hospital, Brighton; C Leen, Western General Hospital, Edinburgh.

Coordinating Centre Staff: J Lundgren (project leader), O Kirk, A Mocroft, N Friis-Møller, A Cozzi-Lepri, W Bannister, M Ellefsen, A Borch, D Podlekarova, J Kjaer, L Peters, J Reekie, J Kowalska

Funding

The European Commission BIOMED 1 (CT94-1637), BIOMED 2 (CT97-2713), the 5th Framework (QLK2-2000-00773) and the 6th Framework (LSHP-CT-2006-018632) programs were the primary sponsors of the study. Unrestricted grants were also provided by Bristol-Myers-Squibb, GlaxoSmithKline, Roche, Gilead, Pfizer, Merck, Tibotec and Boehringer-Ingelheim. The participation of centres from Switzerland was supported by a grant from the Swiss Federal Office for Education and Science.

Transparency declarations

None to declare.
References


